[Characterization of oncological disease: racional, objectives and methodology - perfil study].

Ana Macedo(i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto), Xavier Bonfill(Universitat Autònoma de Barcelona), Sérgio Barroso(Hospital do Espírito Santo), José Dinis(Instituto Português de Oncologia Francisco Gentil), Inês Moital, António Moreira, Francisco Pimentel(Hospital Geral de Fortaleza), N. Afonso, Sofia Andrade

PubMed

April 2, 2009

Cited by 2

Related Papers

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

|The Lancet|2018|1.7k

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

|Annals of Oncology|2012|1.5k

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

|Journal of Clinical Oncology|2011|221

Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

|Annals of Oncology|2017|90

An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

|Cancer Chemotherapy and Pharmacology|2014|87